Genprex has assembled a world-class scientific and medical advisory board, widely recognized as experts in cancer metabolism, oncology, drug discovery and translational medicine. These advisors work in close collaboration with Genprex to identify new research directions and accelerate Genprex’s target validation, drug discovery and development strategies and programs.
Scientific & Medical Advisory Board
Jack A. Roth, MD, FACS, Chairman
Jack A. Roth, MD FACS, is Chairman of the Genprex Scientific and Medical Advisory Board.
Dr. Roth, an internationally renowned cancer expert and oncology pioneer, is Professor and Distinguished Chair of Thoracic Surgery, Professor of Molecular & Cellular Oncology, Director of the Keck Center for Innovative Cancer Therapies, and Chief of Section of Thoracic Molecular Oncology at The University of Texas MD Anderson Cancer Center.
Dr. Roth is a prolific inventor and author with more than 600 peer reviewed publications. He is a pioneer in the clinical use of DNA as therapeutic agents. He is the first clinical investigator approved by the FDA and NIH-RAC to conduct direct patient gene therapy clinical trials. He is an inventor of our key intellectual properties and has over a twenty-year history in developing new cancer therapeutics for commercial application.
George R. Simon, MD, FACP, FCCP
Scientific & Medical Advisor, George Simon M.D., is the Professor of Medicine and Section Chief of Translational Research within the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. He also serves as Medical Director of the MD Anderson Cancer Network. Dr. Simon has numerous publications focused on molecularly targeted therapies in non-small cell lung cancer (NSCLC) and has recently served as principal investigator of Department of Defense funded research around detection of EGFR mutant tumors (2013 to 2016).
Pasi Antero Janne, MD, PhD
Associate Professor of Medicine, Harvard Medical School and clinician at Dana-Farber Cancer Institute Lowe Center for Thoracic Oncology. Dr. Janne is a leading researcher in medical oncology and lung cancer and is Co-Leader of the Lung Cancer Program at Dana-Farber Harvard Cancer Center. His research interests include the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents, as well as mechanisms of sensitivity and resistance targeted cancer therapies.
Tony S.K. Mok, BMSc, MD, FRCPC, FHKCP, FHKAM (Medicine)
A professor in the Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Director. Do. Mok serves as President of the International Association for the Study of Lung Cancer (IASLC), Vice-Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Co-Founder of the Lung Cancer Research Group, a multicenter organization serving the Asian-Pacific region.